PORTFOLIO

We are seeking to build a diversified portfolio of more than 20 molecules across multiple therapeutic areas and modalities.

 
portfolio.jpg
 

 

Since 2016, we have acquired and are rapidly advancing several high-value candidates from IND-enabling through Phase 2.

 
 
bp-pipeline_01.png
 

 

BOS-161721

BOS-161721 is a humanized monoclonal antibody that targets Interleukin-21, a key component in the adaptive immune response, and may play a key role in autoimmune diseases such as lupus among others. BOS-161721 is currently in Phase 1 in patients with systemic lupus erythematosus. This program originated with Medimmune, the global biologics research and development arm of AstraZeneca.
RETURN TO PIPELINE

 

 

BOS-172767

BOS-172767 is an inverse agonist targeting retinoic acid-related orphan nuclear receptor gamma-t (ROR-γt). ROR-γt is the key transcription factor and the master regulator of human Th17 cells, which play an important role in the pathogenesis of a diverse group of immune-mediated diseases, including psoriasis, rheumatoid arthritis, inflammatory bowel disease and asthma. BOS-172767 is currently in Phase 1.
RETURN TO PIPELINE

 

 

BOS-173717

BOS-173717 is a sphingosine 1-phosphate 1 (S1P1) receptor modulator. S1P1 is a validated target for the potential treatment of autoimmune indications. BOS-173717 is currently in Phase 1.
RETURN TO PIPELINE

 

BOS-172722

BOS-172722 is an inhibitor of monopolar spindle 1 (MPS1) checkpoint with potential for the treatment of various cancers. BOS-172722 is currently in Phase 1 in advanced cancer patients. BOS-172722 was discovered at the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London.
RETURN TO PIPELINE

 

 

BOS-172738

BOS-172738 is a highly selective RET (REarranged during Transfection) kinase inhibitor. RET rearrangements and activating mutations are associated with non-small cell lung cancer and medullary thyroid cancer. BOS-172738 is entering phase 1 in cancer patients. This program was originated at Daiichi Sankyo Co., LTD.
RETURN TO PIPELINE

 

 

BOS-1728515

BOS-1728515 is a selective potassium channel blocker in IND-enabling studies for the treatment of atrial fibrillation. BOS-1728515 (formerly F17727) was licensed from Pierre Fabre Pharmaceuticals.
RETURN TO PIPELINE

 

BOS-162262

BOS-162262 is a small molecule inhibitor of metallo-β-lactamase producing bacteria, including New Delhi metallo strains. BOS-162262 is currently in IND-enabling studies.
RETURN TO PIPELINE

 

 

BOS-475

BOS-475 is a novel anti-inflammatory domain selective BET (Bromodomain and Extra-Terminal) inhibitor for the topical treatment for autoimmune diseases. BOS-475 reduces the expression of pro-inflammatory mediators such as IL-17, IL-12, IL-23 and Th1-associated chemokines. BOS-475 was discovered by GlaxoSmithKline and is entering Phase 1.
RETURN TO PIPELINE

 

BOS-228

BOS-228 is a potential best-in-class monobactam with potent activity against both serine and metallo-β-lactamase expressing carbapenem-resistant Enterobacteriaceae (CRE) that has received Fast-Track and Qualified Infectious Disease Product designations from the FDA.  BOS-228 was discovered at Novartis and currently is in Phase 2 for the treatment of gram-negative bacterial infections.
RETURN TO PIPELINE

 

BOS-572

BOS-572 is a beta-lactamase inhibitor (BLi) with activity against multiple beta lactamases, including ESBLs, serine and other Class A, B, and D beta lactamases. BOS-572 protects carbapenems and other beta-lactam antibiotics from the development of drug resistance. BOS-572 was discovered at Novartis and currently is in IND-enabling studies.
RETURN TO PIPELINE

 

BOS-181

BOS-181 is a potential first-in-class oral LpxC inhibitor with potent activity against Pseudomonas aeruginosa. LpxC is a key enzyme in the production of the essential bacterial cell membrane component LPS. BOS-181 was discovered at Novartis and currently is in IND-enabling studies.
RETURN TO PIPELINE

 

BOS-589

BOS-589 is a selective and colon-restricted RET (REarranged during Transfection) kinase inhibitor for the treatment for IBS (Irritable Bowel Syndrome). BOS-589 was discovered by GlaxoSmithKline and is currently entering Phase 2.
RETURN TO PIPELINE

 

BOS-356

BOS-356 is a selective DGAT1 (diacylglycerol acyltransferase 1) inhibitor for the treatment of acne. DGAT is a critical enzyme in the synthesis of triglyceride production, a major component of sebum. BOS-356 was discovered by GlaxoSmithKline and is currently in Phase 1.
RETURN TO PIPELINE

 

BOS-704

BOS-741 is an inhibitor of an undisclosed metabolic target that was discovered by GlaxoSmithKline (GSK) and currently is in IND-enabling studies.
RETURN TO PIPELINE

 

BOS-981 /
BOS-857

BOS-981 and BOS-857 are first-in-class inhibitors of an undisclosed target that were discovered by GlaxoSmithKline (GSK) and currently are in IND-enabling studies.
RETURN TO PIPELINE

 
 

Learn more about how to partner with us.